Dapagliflozin Effects on Epicardial Fat

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02235298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT02235298
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02235298. Randomized; triple masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2020-09-10 (actual). Results posted on 2021-02-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin Effects on Epicardial Fat
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Lead sponsor
University of Miami (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02235298
Content hash
b6944fa29bfae33febf9064c39ed66351022e64dcac10912bb5e5f7c508a9b70